{"id":"NCT00887068","sponsor":"M.D. Anderson Cancer Center","briefTitle":"Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129)","officialTitle":"Randomized Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-04-21","primaryCompletion":"2018-08-20","completion":"2018-08-20","firstPosted":"2009-04-23","resultsPosted":"2020-01-14","lastUpdate":"2020-01-14"},"enrollment":187,"design":{"allocation":"RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Leukemia","AML","MDS"],"interventions":[{"type":"DRUG","name":"Azacitidine","otherNames":["5-Azacitidine","5-aza","Vidaza","5-AZC","AZA-CR","Ladakamycin","NSC-102816"]}],"arms":[{"label":"Azacitidine","type":"EXPERIMENTAL"},{"label":"No Azacitidine","type":"NO_INTERVENTION"}],"summary":"The goal of this clinical research study is to learn if Vidaza (azacitidine) will help to control the disease in patients with AML, CMML, or MDS after an allogeneic (donor) stem cell transplant. The safety of this drug will also be studied.","primaryOutcome":{"measure":"Relapse-free Survival (RFS)","timeFrame":"3 years","effectByArm":[{"arm":"AZA Group","deltaMin":2.1,"sd":0.43},{"arm":"Standard of Care Group","deltaMin":1.3,"sd":0.43}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["33170934"],"seeAlso":["http://www.mdanderson.org"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":87},"commonTop":["Poor Graft function","Thrombocytopenia","Infection","Hepatic","Gastrointestetinal"]}}